Allogeneic Bone Marrow Transplant DRG Reimbursement Guide

DRG 014 describes inpatient admissions for allogeneic bone marrow transplant procedures and associated intensive care needs. This DRG matters for inpatient reimbursement because it captures high-resource services and complications that influence Medicare payment under Diagnosis-Related Group methodology.

DRG 014 Overview

DRG 014 covers inpatient hospital stays for allogeneic bone marrow transplant procedures, including preparative regimens, stem cell infusion, and early post-transplant care. This DRG reflects high-intensity resource use related to immunosuppression, graft-versus-host disease risk, and management of infectious or hematologic complications. It matters for Medicare payment because transplant admissions drive substantial inpatient costs and are reimbursed under Diagnosis-Related Group payment principles that account for clinical complexity. Accurate classification affects payment relative to resource consumption for these complex hematologic and transplant services.

Studies evaluating conditioning regimen intensity and toxicity reduction: randomized or prospective comparative trials examine different preparative (conditioning) regimens — such as reduced-intensity versus myeloablative approaches — in allogeneic bone marrow transplant candidates with hematologic malignancies or marrow failure. These studies enroll adults and/or pediatric patients stratified by disease risk, comorbidity indices, and donor type to measure engraftment, treatment-related mortality, and short-term complications like mucositis and infection. Results inform clinicians and payers about trade-offs between transplant-related toxicity, hospital length of stay, and early resource utilization, helping guide patient selection and coverage decisions.
Comparative effectiveness and immunomodulation trials to prevent or treat graft-versus-host disease (GVHD): interventional and observational studies test prophylactic strategies, dosing schedules, or adjunct immunosuppressive approaches in recipients of allogeneic grafts, including subgroup analyses by donor match (matched related, matched unrelated, or haploidentical) and stem cell source. These trials focus on incidence, severity, and chronicity of acute and chronic GVHD, infection risk, and need for prolonged immunosuppression, enrolling patients across post-transplant timeframes. Findings are highly relevant to providers and payers because GVHD drives substantial inpatient readmissions, prolonged therapy costs, and long-term morbidity that affect resource allocation and reimbursement considerations.
Post-discharge survivorship, infectious complication surveillance, and health services/outcomes research: cohort studies and pragmatic trials assess post-transplant care models, outpatient monitoring protocols, vaccination and antimicrobial prophylaxis strategies, and quality-of-life or functional recovery metrics in transplant recipients after hospital discharge. These studies typically follow patients for months to years to quantify readmission rates, late infections, relapse, graft failure, and outpatient resource use, often comparing centralized transplant clinics versus distributed care pathways. Outcomes directly impact hospital readmission penalties, long-term payer expenditures, and inform pathways intended to reduce avoidable inpatient utilization while optimizing survival and patient-centered outcomes.

Studies evaluating conditioning regimen intensity and toxicity reduction: randomized or prospective comparative trials examine different preparative (conditioning) regimens — such as reduced-intensity versus myeloablative approaches — in allogeneic bone marrow transplant candidates with hematologic malignancies or marrow failure. These studies enroll adults and/or pediatric patients stratified by disease risk, comorbidity indices, and donor type to measure engraftment, treatment-related mortality, and short-term complications like mucositis and infection. Results inform clinicians and payers about trade-offs between transplant-related toxicity, hospital length of stay, and early resource utilization, helping guide patient selection and coverage decisions.
Comparative effectiveness and immunomodulation trials to prevent or treat graft-versus-host disease (GVHD): interventional and observational studies test prophylactic strategies, dosing schedules, or adjunct immunosuppressive approaches in recipients of allogeneic grafts, including subgroup analyses by donor match (matched related, matched unrelated, or haploidentical) and stem cell source. These trials focus on incidence, severity, and chronicity of acute and chronic GVHD, infection risk, and need for prolonged immunosuppression, enrolling patients across post-transplant timeframes. Findings are highly relevant to providers and payers because GVHD drives substantial inpatient readmissions, prolonged therapy costs, and long-term morbidity that affect resource allocation and reimbursement considerations.
Post-discharge survivorship, infectious complication surveillance, and health services/outcomes research: cohort studies and pragmatic trials assess post-transplant care models, outpatient monitoring protocols, vaccination and antimicrobial prophylaxis strategies, and quality-of-life or functional recovery metrics in transplant recipients after hospital discharge. These studies typically follow patients for months to years to quantify readmission rates, late infections, relapse, graft failure, and outpatient resource use, often comparing centralized transplant clinics versus distributed care pathways. Outcomes directly impact hospital readmission penalties, long-term payer expenditures, and inform pathways intended to reduce avoidable inpatient utilization while optimizing survival and patient-centered outcomes.

OpenPayer

Summary & Overview

Allogeneic Bone Marrow Transplant: Inpatient Reimbursement Overview

DRG 014 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes